Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDRigel Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 3 | $0.08 | $0.10 | $0.09 |
| Q2 2025 | 1 | $0.28 | $0.35 | $0.32 |
| Q3 2025 | 1 | $0.27 | $0.34 | $0.31 |
| Q4 2025 | 1 | $0.41 | $0.52 | $0.47 |
Rigel Pharmaceuticals, Inc. Earnings Date And Information
Rigel Pharmaceuticals, Inc. last posted its earnings results on Tuesday, March 4th, 2025. The company reported $0.8 earnings per share for the quarter, topping analysts' consensus estimates of $0.3 by $0.5. The company had revenue of 57.60 M for the quarter and had revenue of 179.28 M for the year. Rigel Pharmaceuticals, Inc. has generated $1 earnings per share over the last year ($0.99 diluted earnings per share) and currently has a price-to-earnings ratio of 20.54. Rigel Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based on prior year's report dates.
Rigel Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/04/2025 | Q4 2024 | $0.30 | $0.82 | 0.52 | $50.10 M | $57.60 M |
| 11/07/2024 | Q3 2024 | $0.06 | $0.71 | 0.65 | $41.94 M | $55.31 M |
| 08/06/2024 | Q2 2024 | -$0.37 | -$0.06 | 0.31 | $33.42 M | $36.84 M |
| 05/07/2024 | Q1 2024 | -$0.30 | -$0.47 | -0.17 | N/A | $29.53 M |
| 03/05/2024 | Q4 2023 | $0.02 | $0.04 | 0.02 | $34.10 M | $35.79 M |
| 11/07/2023 | Q3 2023 | -$0.70 | -$0.33 | 0.37 | $27.20 M | $28.13 M |
| 08/01/2023 | Q2 2023 | -$0.80 | -$0.38 | 0.42 | $25.70 M | $26.89 M |
| 05/02/2023 | Q1 2023 | -$0.90 | -$0.78 | 0.12 | N/A | $26.07 M |
| 03/07/2023 | Q4 2022 | -$0.70 | $0.08 | 0.78 | N/A | $51.28 M |
| 11/03/2022 | Q3 2022 | -$1.30 | -$1.10 | 0.2 | $22.61 M | $22.41 M |
| 08/02/2022 | Q2 2022 | -$1.20 | -$0.78 | 0.42 | $23.65 M | $29.82 M |
| 05/03/2022 | Q1 2022 | -$1.20 | -$1.60 | -0.4 | N/A | $16.74 M |
| 03/01/2022 | Q4 2021 | -$1.30 | -$1.32 | -0.02 | N/A | $20.41 M |
| 11/02/2021 | Q3 2021 | -$1.00 | -$1.23 | -0.23 | $23.56 M | $21.54 M |
| 08/03/2021 | Q2 2021 | -$1.10 | -$0.81 | 0.29 | $20.37 M | $26.27 M |
| 05/05/2021 | Q1 2021 | $0.10 | $2.33 | 2.23 | N/A | $81.02 M |
| 03/02/2021 | Q4 2020 | -$1.00 | -$1.14 | -0.14 | N/A | $18.45 M |
| 11/05/2020 | Q3 2020 | -$1.20 | -$0.84 | 0.36 | $17.24 M | $18.39 M |
| 08/04/2020 | Q2 2020 | -$1.30 | -$1.04 | 0.26 | $13.75 M | $16.02 M |
| 05/05/2020 | Q1 2020 | $1.30 | $1.26 | -0.04 | N/A | $55.76 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Rigel Pharmaceuticals, Inc. Earnings: FAQ's
Rigel Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 3rd, 2025 based offlast year's report dates.
In the previous quarter, Rigel Pharmaceuticals, Inc. (:RIGL) reported $0.8 earnings per share (EPS) to beat the analysts' consensus estimate of $0.3 by $0.5.
The conference call for Rigel Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Rigel Pharmaceuticals, Inc.'s latest earnings report can be read online.
Rigel Pharmaceuticals, Inc. (:RIGL) has a recorded annual revenue of $179.28 M.
Rigel Pharmaceuticals, Inc. (:RIGL) has a recorded net income of $17.49 M.Rigel Pharmaceuticals, Inc. has generated $0.99 earnings per share over the last four quarters.
Rigel Pharmaceuticals, Inc. (:RIGL) has a price-to-earnings ratio of 20.54 and price/earnings-to-growth ratio is 0.06.